Tourmaline Bio Inc (TRML)

$16.40 +0.07 (0.43%)
Market Cap 423.11M
Revenue (ttm) 0.00
Net Income (ttm) -42.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 277,000
Avg Vol 210,476
Day's Range N/A - N/A
Shares Out 25.64M
Stochastic %K 12%
Beta 2.36
Analysts Strong Sell
Price Target $53.25

Latest News on TRML

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

Jan 10, 2025, 7:30 AM EST - 20 days ago

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

Dec 10, 2024, 8:30 AM EST - 7 weeks ago

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

Nov 14, 2024, 7:30 AM EST - 2 months ago

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 7, 2024, 7:30 AM EST - 3 months ago

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Tourmaline Bio to Present at Upcoming Investor Conferences

Oct 31, 2024, 7:30 AM EDT - 3 months ago

Tourmaline Bio to Present at Upcoming Investor Conferences

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024

Oct 15, 2024, 7:30 AM EDT - 3 months ago

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024

Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting

Oct 13, 2024, 10:29 AM EDT - 3 months ago

Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting

Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress

Oct 11, 2024, 7:30 AM EDT - 3 months ago

Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress

Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board

Oct 8, 2024, 7:30 AM EDT - 4 months ago

Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board

Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 8, 2024, 7:30 AM EDT - 6 months ago

Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024

Aug 2, 2024, 4:30 PM EDT - 6 months ago

Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

Jun 27, 2024, 8:05 AM EDT - 7 months ago

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

May 23, 2024, 7:10 AM EDT - 9 months ago

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

May 16, 2024, 7:00 AM EDT - 9 months ago

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 13, 2024, 7:00 AM EDT - 9 months ago

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Mar 19, 2024, 7:00 AM EDT - 11 months ago

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 1, 2024, 8:00 AM EST - 1 year ago

Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jan 29, 2024, 4:01 PM EST - 1 year ago

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Tourmaline Bio Announces Pricing of Public Offering of Common Stock

Jan 25, 2024, 7:00 AM EST - 1 year ago

Tourmaline Bio Announces Pricing of Public Offering of Common Stock

Tourmaline Bio Announces Proposed Public Offering of Common Stock

Jan 24, 2024, 4:05 PM EST - 1 year ago

Tourmaline Bio Announces Proposed Public Offering of Common Stock

Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)

Jan 8, 2024, 7:00 AM EST - 1 year ago

Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)

Tourmaline Bio added to the NASDAQ Biotechnology Index

Dec 15, 2023, 4:00 PM EST - 1 year ago

Tourmaline Bio added to the NASDAQ Biotechnology Index

Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

Dec 14, 2023, 7:30 AM EST - 1 year ago

Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

Tourmaline Bio: TED And ASCVD Targeting With Differentiated IL-6

Nov 1, 2023, 2:09 PM EDT - 1 year ago

Tourmaline Bio: TED And ASCVD Targeting With Differentiated IL-6

Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million

Oct 19, 2023, 5:37 PM EDT - 1 year ago

Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

Oct 17, 2023, 5:47 PM EDT - 1 year ago

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

Oct 6, 2023, 5:09 PM EDT - 1 year ago

Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

Oct 4, 2023, 8:30 AM EDT - 1 year ago

New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS

Sep 28, 2023, 2:47 PM EDT - 1 year ago

TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

Jun 22, 2023, 7:30 AM EDT - 1 year ago

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

Talaris Therapeutics Announces Leadership Transition

May 26, 2023, 7:00 AM EDT - 1 year ago

Talaris Therapeutics Announces Leadership Transition

Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan

Feb 16, 2023, 7:00 AM EST - 2 years ago

Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan

Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference

Nov 22, 2022, 7:00 AM EST - 2 years ago

Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference

Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update

Nov 10, 2022, 7:00 AM EST - 2 years ago

Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update

Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance

Nov 7, 2022, 7:00 AM EST - 2 years ago

Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance

Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial

Oct 20, 2022, 8:24 AM EDT - 2 years ago

Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial

Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial

Oct 20, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial

Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting

Oct 17, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting

Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa

Oct 4, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa

Talaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event

Sep 21, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event

Talaris Therapeutics to Participate in Two Upcoming Investor Conferences

Sep 6, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics to Participate in Two Upcoming Investor Conferences

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

Aug 29, 2022, 7:59 AM EDT - 2 years ago

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update

Aug 15, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update

Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update

Jun 30, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update

Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

Jun 7, 2022, 4:01 PM EDT - 2 years ago

Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study

Jun 1, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study

Talaris Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics to Present at the Jefferies Healthcare Conference

Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022, 4:01 PM EDT - 2 years ago

Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Talaris Therapeutics Announces Changes to Board of Directors

May 17, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics Announces Changes to Board of Directors